72%. We also use them to share usage. - TH1902 Phase 1 basket trial proceeding as planned. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. There are 102 news items for this page. com. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. Cookies are used to offer you a better browsing experience and to analyze our traffic. com. Stockhouse. (Image via Theralase Technologies Inc. Following the release, Knight will hold a conference call and audio webcast. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. MONTREAL, Oct. com. MONTREAL, Dec. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. Shares of Theratechnologies are up 4. 00, suggesting a possible upside of. Website. The company had revenue of $20. Pour les émetteurs. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. This news release constitutes a “designated news release” for the purposes. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. FY2022 revenue. 06 million, an increase of 14. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. com. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. Montreal-based biopharmaceutical company Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. -4. We currently market prescription products for people with HIV in the United States. The abstracts are now available at aacr. 9 million as at August 31, 2023. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies. 67% from the latest price. 23 to a day high of $1. com uses cookies on this site. 23) earnings per share over the last year ( ($1. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (882) posted 3 minutes ago. MONTREAL, Oct. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. com uses cookies on this site. About Us | Theratechnologies Inc. Gary Littlejohn Stockhouse. We also use them to share. Stockhouse. By continuing to use our service, you agree to our use of cookies. Revenues have been growing at an average rate of 10. 4 million. By continuing to use our service, you agree to our use of cookies. Vice President, Communications and Corporate Affairs. 86%. Theratechnologies Inc. NCU. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 17. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Theratechnologies, Inc. THTX | Complete Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. We also use them to share usage. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. com uses cookies on this site. com. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Message Board Total Posts: 4. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. Theratechnologies layoffs. 74M. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Provides Details About R&D Day Webcast. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Theratechnologies Inc. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. T. In 2022, THTX's revenue was 80. com. 40 f102M H1. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. . See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. com. We currently market prescription products for people with. Katana shareholders will. 521. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. The webinar will also address system-level barriers and present real-world. Agreement in principle on key amendments to loan. : Nasdaq Theratechnologies Inc. 2. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. We also use them to share usage. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. com uses cookies on this site. Senior Director, Investor Relations. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies inc. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. This news release constitutes a “designated news release” for the purposes of the Company’s. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. The company develops treatments for lipodystrophy . 89 52. 24 million, 48. com uses cookies on this site. . Stockhouse. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Cookies are used to offer you a better browsing experience and to analyze our traffic. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. e. T. MONTREAL, Feb. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. If you have HIV, it's important to know the difference. Stockhouse. 26 +15. 81 million for the quarter. TH | October 13, 2022. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Investor Relations. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. Focused on small-cap companies and sectors. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (THTX) Stock Price, News & Analysis $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Competitors: Unknown. Cookies are used to offer you a better browsing experience and to analyze our traffic. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. com uses cookies on this site. Montréal, Québec, Canada . Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 10% most volatile stocks in CA Market. stock news by MarketWatch. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Once expert advice is considered, the Company. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Elif McDonald - Senior Director, Investor Relations. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. - October 10, 2023) - KO Gold Inc. com uses cookies on this site. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. View recently published Stock News reports from independent reports and journalists. 3. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. P. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. 5% workforce reduction. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. THERATECHNOLOGIES INC. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. com uses cookies on this site. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30,. We changed the address of the Stockhouse website from to stockhouse. com. MONTREAL, Jan. (2013-04-03 | TSX:TH) Theratechnologies Inc. Stockhouse. 8. ET. com uses cookies on this site. Stockhouse. Biopharmaceutical company Theratechnologies Inc. 05M. By continuing to use our service, you agree to our use of cookies. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. T. S. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. 65 per cent to C$1. MONTREAL, Dec. The company reported ($0. MONTREAL, Oct. US Headquarters. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. 72%. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. T. Trogarzo® and. Theratechnologies's earnings have been declining at an average annual rate of -35. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Remember, high Theratechnologies' alpha is almost always a sign of. By continuing to use our. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - 2023 Q3 positive adjusted EBITDA to be. By continuing to use our service, you agree to our use of cookies. One reason for that is that this tier does not include penny stocks. com uses cookies on this site. - Q3 2022 North American Revenue Growth of 19%. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Cookies are used to offer you a better browsing experience and to. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Theratechnologies Appoints New Board Member. 10% least volatile stocks in CA Market. 20% from a day low at $1. com uses cookies on this site. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. stock news by MarketWatch. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. T. (2013-04-03 | TSX:TH) Theratechnologies Inc. 38. sBLA for F8 formulation of tesamorelin submitted to FDA. 08 (+6. MONTREAL, Oct. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. . TORONTO, May 19, 2023. (“Theratechnologies”) with the Securities and Exchange Commission (the. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. We also use them to share usage. NEW YORK, Dec. 81 million for the quarter. 63. com uses cookies on this site. com uses cookies on this site. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Communications & Corporate Affairs. It is the Company’s proprietary peptide linked to. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. Stockhouse. is an employee of TaiMed Biologics USA, Inc. Stockhouse. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. 9%, while the Biotechs industry saw earnings growing at 17. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. Market Cap. Stockhouse. L. Northwest also announces an update on its. This news release constitutes a "designated news release" for the purposes of. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. Stockhouse. - Q3 2022 Consolidated. 4% from the stock's current price. ET. THERATECHNOLOGIES INC. Stockhouse. com uses cookies on this site. GlobeNewswire. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. Theratechnologies Inc. 2 million. Paul Levesque - President. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies Inc. 86 million for the quarter. 66% compared to the previous year's 69. Stockhouse. com uses cookies on this site. US Headquarters. Wainwright NASH Investor Conference. Microsoft to invest $500M in Quebec AI economy. Track Theratechnologies Inc. com. S. TH | May 19, 2023. Biopharmaceutical company Theratechnologies Inc. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 54% and a negative trailing twelve-month return on equity of 1,116. 124. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. was a. About SORT1+ Technology™ and TH1902. Company Type For Profit. GUD | Complete Knight Therapeutics Inc. Image source: The Motley Fool. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share. (TH. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. ET. RESSOURCES. Their THTX share price targets range from $36. [email protected] Inc: Overview. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. com uses cookies on this site. These pharmaceuticals. 617-356-1009. TH | February 28, 2023. Stockhouse. 4% annually. Shares of Theratechnologies are up 4. Register for your free account today at data. com uses cookies on this site. Stockhouse. 54% and a negative trailing twelve-month return on equity of. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. 25. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. T.